Vitamica wins Best Elevator Pitch at SETsquared Bristol’s Tech-Xpo 2019
The Future Space tenant took home the prize after a fantastic pitch from CTO Charlotte Bermingham.
We are delighted to see that Vitamica is already getting recognised by industry experts since joining the Future Space community in April.
The medical diagnostics company is changing the way clinicians make decisions around antibiotics. Just over a year old, the spin-out from the University of Bristol is developing the technology to test pathogenic bacteria for susceptibility to antibiotics within just one hour.
Vitamica is working to combat the growing global challenge of antimicrobial resistance (AMR) among infectious bacteria using antimicrobial susceptibility testing (AST) technology to reduce the time it takes for clinicians to accurately assign effective antibiotics.
This month, the company was recognised at SETsquared Bristol’s Tech-Xpo after the audience were won over by CTO Charlotte Bermingham’s 60-second pitch of Vitamica.
All eight companies that pitched were filmed presenting to a crowd of investors, academics and business leaders, who ultimately decided the winner, and Vitamica took home the award for ‘Best Elevator Pitch’ on the night.
Future Space is proud to have Vitamica as a resident, utilising the laboratories to conduct its revolutionary testing and developing is commercial identity in the Bristol life sciences sector.
We’re excited to see what the future holds for Vitamica!
More Case Studies
West of England Academic Health Science Network (AHSN) at Future Space
We caught up with project manager Rosie Brown and project support officer Chris Padgett, to find out more about their work and how being at Future Space is integral to the organisation.
Q&A: Luke Loveridge, CEO at Homelync
“We’re working to address many of the problems faced by social landlords, including making homes more energy efficient, keeping rent affordable and supporting people living in their homes for longer”
Q&A: Charlotte Bermingham, CTO at Vitamica
“We are working to address the global challenge of antimicrobial resistance…aiming to transform the way clinicians make decisions on antibiotic prescription.”